Rangeley Capital, LLC An2 Therapeutics, Inc. Transaction History
Rangeley Capital, LLC
- $93.4 Billion
- Q1 2025
A detailed history of Rangeley Capital, LLC transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Rangeley Capital, LLC holds 50,000 shares of ANTX stock, worth $60,500. This represents 0.07% of its overall portfolio holdings.
Number of Shares
50,000Holding current value
$60,500% of portfolio
0.07%Shares
1 transactions
Others Institutions Holding ANTX
# of Institutions
38Shares Held
13.7MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$6.96 Million6.33% of portfolio
-
Almitas Capital LLC Santa Monica, CA1.31MShares$1.59 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.25 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1MShares$1.21 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY581KShares$702,8320.89% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $23.5M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...